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Autoimmune diseases are caused by multiple   
genetic and/or environmental factors and are 
characterized by immune hyperactivity (Marrack   
et al., 2001; Mathis and Benoist, 2004). Certain 
autoimmune diseases are thought to develop 
in specific tissues as a result of cognate antigen 
recognition by CD4+ T cells, particularly when 
these diseases are associated with class II MHC 
alleles, as is the case with rheumatoid arthritis 
(RA;  Steinman,  2001;  Zhang  et  al.,  2008;   
Imboden, 2009). Consistent with this, joint- 
specific antigenic peptides have been identified in   
humans (derivatives of aggrecan, fibrillin, colla-
gen, etc.; Polgár et al., 2003; Chapuy-Regaud   
et  al.,  2005;  Elsaid  and  Chichester,  2006; 
Takizawa  et  al.,  2006; Van  Steendam  et  al., 
2010). Furthermore, immunodominant MHC 
class II peptides in a collagen-induced arthritis 
model have been found to match those seen in 
human RA (Andersson et al., 2010), although 
whether these peptides are a result rather than 
a cause of joint damage is unclear. Therefore, 
the  mechanisms  that  determine  tolerance  to 
self-antigens are central to understanding the 
pathogenesis of autoimmune diseases. Despite 
the evidence for antigen-specific T cell acti-
vation in these diseases, tissue-specific self- or 
nonself-antigens recognized by activated CD4+ 
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Cognate antigen recognition by CD4+ T cells is thought to contribute to the tissue specificity of 
various autoimmune diseases, particularly those associated with class II MHC alleles. However, 
we show that localized class II MHC–dependent arthritis in F759 mice depends on local events 
that result in the accumulation of activated CD4+ T cells in the absence of cognate antigen 
recognition. In this model, transfer of in vitro polarized Th17 cells combined with the induction 
of experimental microbleeding resulted in CCL20 production, the accumulation of T cells in the 
joints, and local production of IL-6. Disease induction required IL-17A production by transferred 
T cells, IL-6 and CCL20 expression, and STAT3 signaling in type I collagen–expressing cells. Our 
data suggest a model in which the development of autoimmune disease in F759 mice depends 
on four events: CD4+ T cell activation regardless of antigen specificity, local events that induce 
T cell accumulation, enhanced sensitivity to T cell–derived cytokines in the tissue, and activation 
of IL-6 signaling in the tissue. This model provides a possible explanation for why tissue-specific 
antigens recognized by activated CD4+ T cells have not been identified in many autoimmune 
diseases, especially those associated with class II MHC molecules.
©  2011  Murakami  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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Of special interest is IL-6, which several studies have 
suggested  has  an  important  role  in  autoimmune  diseases 
(Hirano,  1998,  2010;  O’Shea  et  al.,  2002;  Sakaguchi  and 
Sakaguchi, 2005; Awasthi and Kuchroo, 2009). The F759 
knockin mouse line (F759), for example, which expresses a 
mutant variant of the IL-6 signaling transducer gp130 where 
the 759th tyrosine residue is substituted with phenylalanine 
(F),  shows  enhanced  IL-6–mediated  STAT3  activation  as   
the result of a lack of SOCS3-medaited suppression (Ohtani   
et al., 2000; Sawa et al., 2006). As these mice age, they spon-
taneously develop an RA-like MHC II–associated tissue-
specific disease, indicating that constitutive activation of 
IL-6 signaling is involved in the development of some auto-
immune diseases (Atsumi et al., 2002; Sawa et al., 2006). 
Moreover, anti–IL-6 receptor therapy is effective for some 
RA patients (Nishimoto and Kishimoto, 2004), supporting 
the use of F759 mouse as a mouse model for RA. Further-
more, we have previously shown that MHC II–restricted 
CD4+ T cells, but not CD8+ T cells and B cells, enhance the 
development of arthritis in F759 mice (Sawa et al., 2006), 
whereas a subset of CD8+ T cells expressing Foxp3 negatively 
regulates arthritis development in these mice (Nakagawa   
et al., 2010). We have further demonstrated that excess IL-6 
signaling in type I collagen+ cells induces the T cell survival 
factor IL-7, which increases the memory/activated pheno-
type of CD4+ T cells via an increase in homeostatic prolif-
eration, a process which is critical for arthritis development 
in F759 mice (Sawa et al., 2006). This suggests that the   
interaction between nonimmune tissue (type I collagen+ 
cells in F759 mice) and immune tissue (activated CD4+  
T cells in F759 mice) plays important roles in this model of 
autoimmune  disease  (Hirano,  2010).  Moreover,  IL-17A– 
expressing CD4+ T cells that express a memory/activated 
phenotype exist in vivo, including in F759 mice (Nishihara 
et al., 2007; Ogura et al., 2008), and arthritis in F759 mice is 
dependent on IL-17A (Ogura et al., 2008). Thus, it is plausi-
ble that an age-dependent increase in homeostatic prolif-
eration via IL-6–mediated IL-7 expression plays a role in 
the accumulation of antigen-experienced memory/activated 
T cells in many class II MHC–associated diseases have not 
been well established (Mocci et al., 2000; Skapenko et al., 
2005). This raises the possibility that a breakdown in CD4+  
T cell tolerance for a tissue-specific antigen is not always 
crucial for the development of autoimmune diseases. Instead, 
CD4+ T cell activation may be the consequence of events 
initiated by inflammation triggered by certain genetic and/or 
environmental factors in the affected tissues (Hirano, 1998; 
Matsumoto et al., 1999; Marrack et al., 2001). In these cases, 
direct and/or indirect cytokine production rather than cog-
nate antigen recognition by activated CD4+ T cells may be 
critical for the resulting tissue specificity. In fact, various sub-
sets of effector CD4+ T cells—for example, Th1 cells, Th2 
cells, and Th17 cells, which express high levels of IFN-, IL-4,   
and  IL-17A,  respectively  (Mosmann  and  Coffman,  1989; 
Glimcher and Murphy, 2000; Cua et al., 2003; Harrington 
et al., 2005; Park et al., 2005; Veldhoen et al., 2006; Zhu   
et al., 2006; Bettelli et al., 2007)—may initiate and drive the 
progression of disease even though cytokine production by   
T cells is dependent on TCR cross-linking.
Additionally,  there  exists  an  age-dependent  increase  in 
memory/activated phenotype CD4+ T cells resulting from 
homeostatic proliferation mediated by a reduction in T cell 
input from the thymus (Surh and Sprent, 2000). Moreover, it 
has been reported that an age-dependent reduction in naive 
CD4+ T cells in the periphery increases the likelihood of   
(a) weak interactions between TCRs and peptides presented 
by self-class II MHC molecules, which include autoantigenic 
peptides involved in the positive selection, and (b) cytokine 
consumption per CD4+ T cell, including the T cell survival 
factor IL-7 (Surh and Sprent, 2000). Furthermore, we and 
others have shown that homeostatic proliferation of CD4+  
T cells is involved in the development of diabetes, arthritis, 
and Omenn syndrome (King et al., 2004; Jang et al., 2006; 
Sawa et al., 2006; Khiong et al., 2007). This process is also as-
sociated with a specific cytokine profile that includes IL-17A 
and  IFN-  from  homeostatic  proliferating  CD4+ T  cells 
(Gudmundsdottir  and Turka,  2001;  Khiong  et  al.,  2007;   
Nishihara et al., 2007).
Figure 1.  F759 mice expressing a single 
TCR variant that recognizes a nonjoint  
antigen develop arthritis. (a and b) Clinical 
arthritis scores for RAG2/ F759-P25 mice 
(black circles in a; n = 76, 73, 62, 56, 46, 30, 14, 
and 7 for 1, 2, 3, 4, 5, 6, 7, and 8 mo, respec-
tively) and RAG2/ F759-OT2 (black circles in b; 
n = 5, 5, 5, 7, 8, and 2 for 1, 2, 3, 4, 5, and 6 mo,  
respectively) were determined as described in 
Materials and methods and compared with 
scores for control RAG2/ F759, RAG2/ 
F759+/ P25, and RAG2/ F759+/ OT2 mice. 
Control RAG2/ F759 (open squares in a and b; 
n = 15), RAG2/ F759+/ P25 mice (open 
circles in a; n = 47, 47, 40, 37, 31, 20, 10, and 6 for 1, 2, 3, 4, 5, 6, 7, and 8 mo, respectively), and RAG2/ F759+/ OT2 mice (open circles in b; n = 36, 36, 28, 
22, 17, and 9 for 1, 2, 3, 4, 5, and 6 mo, respectively) were also examined (RAG2/ F759+/ TCR Tg mice vs. RAG2/ F759-TCR Tg mice; *, P < 0.05; ***, P < 0.005). 
The mean scores ± SEM were determined as described in Materials and methods. P-values were calculated using Student’s t tests.JEM VOL. 208, January 17, 2011 
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RESULTS
Cognate antigen recognition by CD4+ T cells is not required 
for the development of arthritis in F759 mice
As previously reported, F759RAG/ mice did not develop   
arthritis as they aged (Sawa et al., 2006; Ogura et al., 2008; Fig. 1,   
a and b). Arthritis did develop in F759 mice engineered to   
express a single TCR variant that recognizes a nonjoint antigen 
associated with tuberculosis (F759RAG/-P25) or ovalbumin 
(F759RAG/-OT2) but not in either F759+/ RAG/-P25 
or F759+/ RAG/-OT2 mice (Fig. 1, a and b). Histology 
analysis confirmed these results by monitoring cell accumulation 
in the synovial regions (Fig. S1, a and b). Furthermore, total cell 
numbers from spleen and lymph node tissues, total numbers of 
CD4+ T cells, memory/activated CD4+ T cells, and IL-17A– 
expressing CD4+ T cells and serum concentrations of IL-17A 
and IL-6 were all significantly higher in F759RAG/-P25 mice 
than in either control (RAG/-P25) or F759+/ RAG/-P25 
(Fig. 2, a–f). These results suggest that cognate antigen recogni-
tion by CD4+ T cells is not essential for the tissue specificity in 
F759 mouse suffering from CD4+ T cell–dependent arthritis.
A local event that induces Th17 cell accumulation plays  
a role in the development of arthritis via the activation  
of IL-6 signaling
We hypothesized that local events in the joint may contribute 
to the determination of autoimmune disease specificity by 
phenotype CD4+ T cells expressing IL-17A. This is espe-
cially true for those F759 mice that show excess IL-6 signal-
ing.  We  previously  showed  that  an  IL-17A–triggered 
positive-feedback  loop  that  results  in  IL-6  expression,  as 
well as chemokine expression in type I collagen+ cells, is 
enhanced in the presence of IL-6 in a manner dependent on 
NF-B and STAT3 (Ogura et al., 2008). We named this   
IL-17A–dependent IL-6 amplification loop “the IL-6 am-
plifier” (Ogura et al., 2008; Hirano, 2010). Importantly, acti-
vation  of  this  IL-6  amplification  loop  is  critical  for  the 
development of arthritis in F759 mice and in MOG antigen-
specific T cell–mediated experimental autoimmune encephalo-
myelitis (EAE; Ogura et al., 2008).
In this paper, we investigate how tissue-specific disease 
develops in F759 mice and sought to identify the triggering 
factor for the IL-6 amplification loop in the joints of F759 
mice. Our results demonstrate that cognate antigen recogni-
tion by effector CD4+ T cells is not necessary for tissue speci-
ficity in this arthritis model. Rather, we suggest that local 
events, including microbleeding in the affected tissue, deter-
mine the specificity via Th17 cell accumulation and activa-
tion of the IL-17–dependent IL-6 amplification loop. Based 
on our results, we propose that certain class II MHC–associated 
autoimmune diseases such as RA arise through a series of at 
least four steps that are independent of tissue antigen recogni-
tion by CD4+ T cells.
Figure 2.  F759 mice expressing a single TCR variant that recognizes a nonjoint antigen show homeostatic induction of Th17 cell development.  
Total cells (a), CD4+ T cells (b), memory/activated CD4+ T cells (c), and Th17 cells (d) were counted in spleen and lymph node tissues isolated from 6-mo-old RAG2/ 
F759-P25 mice (n = 14) or control mice (n = 11: RAGKO-P25 [n = 3] and F759+/ RAGKO-P25 [n = 8]). (e and f) Serum concentrations of IL-17A and IL-6 were ana-
lyzed in 6-mo-old RAG2/ F759-P25 mice (n = 9 and 10, respectively) and control mice (n = 15 and 10, respectively). The number of total cells (***, P < 0.005),  
CD4+ T cells (*, P < 0.05), memory/activated CD4+ T cells (*, P < 0.05), and Th17 cells (*, P < 0.05), as well as the serum concentrations of IL-17A (*, P < 0.05) and IL-6 
(*, P < 0.05), were all significantly higher in 6-mo-old RAG2/ F759-P25 mice. P-values were calculated using Student’s t tests. Horizontal bars indicate mean.106 Ag-independent induction of MHC2 autoimmunity | Murakami et al.
Figure 3.  Microbleeding contributes to the development of arthritis in F759 mice. (a) Clinical arthritis scores from the left legs of control 
C57BL/6 mice (open triangles; n = 4) and F759 mice (open circles; n = 4) subjected to microbleeding and intravenously injected with 5 × 106 Th17 cells  
(*, P < 0.05; **, P < 0.01; ***, P < 0.005 for 3, 5, 6, 7, 9, 10, 13, and 14 d, respectively). (b) Clinical arthritis scores from the right legs of F759 mice (open 
circles; n = 4) or C57BL/6 mice (open triangles; n = 4) after injections of 5 × 106 Th17 cells without microbleeding induction. (c) Clinical arthritis scores 
from the legs of F759 mice injected with 5 × 106 Th17 cells and subjected to microbleeding (closed circles; n = 5) or F759 mice injected with 5 × 106 acti-
vated nonpolarized CD4+ T cells and subjected to microbleeding (closed triangles; n = 5). Results were compared with clinical arthritis scores from the 
legs of F759 mice not subjected to microbleeding (open circles: mice receiving Th17 cells [n = 5]; **, P < 0.01; ***, P < 0.005 for 12, 14, 15, and 16 d; open 
triangles: mice receiving activated, nonpolarized CD4+ T cells [n = 5]). (d) Clinical arthritis scores from the legs of F759 mice subjected to microbleeding 
without transfers of effector T cells are also shown (open triangles; n = 4) and compared with scores from the legs of F759 mice injected with 5 × 106 
Th17 cells and subjected to microbleeding (open circles; n = 4; *, P < 0.05; ***, P < 0.005 for 6, 7, 10, 11, 13, and 14 d, respectively). (e) Number of total 
cells, CD4+ T cells, CD4+CD45.1+ T cells, and CD4+CD45.1+CCR6+ T cells from joint tissues of F759 mice that received transfers of 2 × 107 Th17 cells in the 
presence or absence of microbleeding induction (24 h after transfer) were analyzed (untreated vs. microbleeding: *, P < 0.05; ***, P < 0.005). Horizontal 
bars indicate mean. (f) Joint tissues of F759 mice that did or did not receive transfers of 5 × 106 Th17 cells in the presence or absence of microbleeding JEM VOL. 208, January 17, 2011 
Article
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were prepared. IL-6 mRNA expression levels were analyzed (no microbleeding vs. microbleeding in the presence of intravenous injection of Th17 cells:  
*, P < 0.05). (g) Clinical arthritis scores from the legs of F759 mice after intravenous transfer of Th17 cells derived from C57BL/6 mice (open circles; n = 7) 
or IL-17A/ mice (open triangles; n = 5). All mice were subjected to microbleeding (WT vs. IL-17A/ Th17 cells: *, P < 0.05 for 10, 11, 12, and 14 d).  
(h and i) Clinical arthritis scores from the legs of positive control F759 mice (open circles; n = 8 for IL-6/ F759 mouse experiment; n = 10 for type I col-
lagen-Cre STAT3flox/flox F759 mouse experiment) compared with those from the legs of IL-6–deficient F759 mice (crosses; n = 6 in h) or type I collagen-Cre 
STAT3flox/flox F759 mice (closed squares; n = 6 in i) after intravenous transfer of 5 × 106 WT Th17 cells and microbleeding induction (IL-6–deficient F759:  
*, P < 0.05 for 9, 10, 13, and 15 d; type I collagen-Cre STAT3flox/flox F759 mice: *, P < 0.05; **, P < 0.01; ***, P < 0.005 for 7, 8, 10, 12, and 15 d). The mean 
scores ± SEM were determined as described in Materials and methods. P-values were calculated using Student’s t tests. These experiments were per-
formed at least twice independently. Representative data are shown.
 
triggering Th17 cell accumulation, which in turn enhances 
IL-6  signaling  via  the  IL-17–triggered  IL-6  amplification 
loop. It is known that microbleeding, which occurs even in 
the joints of healthy individuals, can trigger hemarthrosis in 
hemophilia patients because of defects in blood coagulation 
(Aledort et al., 1994; Manco-Johnson et al., 2007; Hakobyan 
et al., 2008). Interestingly, like arthritis in F759 mice, hemar-
throsis most often affects the ankles (Manco-Johnson et al., 
2007). Therefore, we hypothesized that experimental micro-
bleeding in F759 mice might trigger arthritis in the presence 
of Th17 cells.
We  first  induced  the  development  of  effector  CD4+  
T cells including Th17 cells and activated nonpolarized 
CD4+ T cells in vitro (Fig. S2). It is of note that sorting the   
CD4+ T cell population revealed that the overall TCR-V 
profile was not perturbed (unpublished data). We transferred 
the sorted cells into young F759 mice without arthritis symp-
toms and experimentally induced microbleeding in one leg. 
This resulted in arthritis in the leg in which microbleeding 
was induced but not in the other legs (Fig. 3, a and b). Th17 
cell transfer alone did not induce arthritis (Fig. 3 c) but re-
sulted in disease if preceded by the induction of microbleed-
ing (Fig. 3 c). This was confirmed by histology (Fig. S1, d and e). 
Transfer of nonpolarized effector CD4+ T cells or Th1 cells 
also triggered a mild form of arthritis if preceded by micro-
bleeding (Fig. 3 c and Fig. S3), whereas microbleeding alone 
did not cause disease in F759 hosts (Fig. 3 d). Control C57BL/6 
(WT) hosts did not develop arthritis under any condition 
(Fig. 3, a and b). We also showed that transferred Th17   
cells maintain their phenotype by monitoring IL-17A–GFP 
expression  in  the  joints  after  microbleeding  induction   
(Fig. S4). Thus, we conclude that arthritis in F759 mice is 
triggered by local microbleeding in a manner dependent on 
the presence of Th17 cells in the blood and lymphoid organs. 
Moreover, because arthritis developed in F759 mice but not 
in control C57BL/6 hosts after the same treatment, enhanced 
sensitivity to cytokines in the given tissue is required for dis-
ease development.
After the induction of microbleeding, the number of   
effector CD4+ T cells, including CCR6+ T cells, increased   
in the joints of F759 mice that received congenic Th17 cells 
(Fig. 3 e). Additionally, the expression level of IL-6 increased 
in the joint tissues when microbleeding was accompanied by 
a transfer of Th17 cells (Fig. 3 f). Furthermore, F759 mice that 
received Th17  cells  derived  from  IL-17A–deficient  mice 
showed a mild form of arthritis after microbleeding was in-
duced (Fig. 3 g). IL-6–deficient F759 mice and F759 mice in 
which STAT3 was deleted in type I collagen+ cells did not 
develop arthritis even after Th17 cell transfer and joint micro-
bleeding induction (Fig. 3, h and i). These results suggest that 
a local event like microbleeding induces Th17 cell accumula-
tion and IL-6 signaling in the joints, most likely via activation 
of the IL-17A–mediated IL-6 amplification loop.
CCL20, a target gene of the IL-17–dependent IL-6 
amplification loop in type 1 collagen+ cells, is required  
for Th17 accumulation and arthritis development
We next attempted to identify the critical target gene of the 
IL-6 amplification loop that induces local accumulation of 
effector CD4+ T cells, including Th17 cells, hypothesizing 
that chemokines like CCL20, a chemotactic factor for Th17 
cells, might be involved (Williams, 2006; Hirota et al., 2007). 
We speculated that microbleeding in the joints initially in-
duces a limited accumulation of Th17, which, in turn, may 
induce a stable level of chemokine expression. Chemokine 
expression may then magnify Th17 cell accumulation and   
enhance  IL-6  signaling  at  the  relevant  site.  Indeed,  we 
found that CCL20 expression synergistically increased when 
type 1 collagen+ fibroblasts were stimulated with IL-6 and   
IL-17A (Fig. 4 a). Moreover, CCL20 expression levels and 
CD4+CCR6+ T cell numbers were higher among synovial 
tissues isolated from older F759 mice with arthritis compared 
with those from control mice (Fig. 4, b and c). Also, F759 
mice that were transferred with Th17 cells developed arthritis 
upon injection of CCL20 into the joint (Fig. 4 d and Fig. S1 c). 
Arthritis did not develop in the joint of the leg subjected to 
vehicle injection (Fig. S5). No arthritis was observed in con-
trol C57BL/6 animals, which were similarly treated (Fig. S5 
and Fig. 4 d). We also observed that microbleeding induces 
CCL20 expression in the joints of F759 mice that received 
Th17 cell transfer (Fig. 4 e). These results support the idea that 
local microbleeding induces CCL20 expression in the joints, 
which causes tissue-specific but antigen-nonspecific accumu-
lation of CCR6+ Th17 cells. Furthermore, F759 mice that re-
ceived IL-17A–deficient Th17 cells or Th1 cells showed lower 
clinical arthritis scores even after joint injections of CCL20 
(Fig. 4 f and Fig. S3). Neither IL-6–deficient F759 mice nor 
F759 mice in which STAT3 was deleted in type I collagen+ 
cells developed arthritis, even after Th17 cell transfer followed 
by joint injections of CCL20 (Fig. 4, g and h). In addition,   108 Ag-independent induction of MHC2 autoimmunity | Murakami et al.
indicate that microbleeding, which induces Th17 cell accu-
mulation, enhances IL-6 signaling in type I collagen+ cells   
in joints. This then gives rise to the development of CD4+  
local microbleeding failed to induce arthritis in F759 mice 
with Th17 cell transfer if either CCL20 or STAT3 expres-
sion was knocked down in the joints (Fig. 4 i). Thus, our results   
Figure 4.  CCL20 contributes to the development of arthritis in F759 mice. (a) Mouse embryonic fibroblast (MEF) cells and synovial fibroblasts 
were prepared and stimulated with human IL-6 + soluble IL-6R and/or IL-17A for 3 h. Cells were harvested and total RNA were collected and assessed 
with real-time PCR for CCL20. (***, P < 0.005 for IL-6 and IL-17A). (b and c) Cells from F759 and C57BL/6 joints were prepared and CCL20 mRNA expres-
sion levels and CD4+CCR6+ T cell percentages were analyzed. (*, P < 0.05; ***, P < 0.005 for 8-wk-old [8wo] C57BL/6, 12-mo-old [12mo] C57BL/6,  
8-wk-old F759, and 12-mo-old spontaneous arthritic F759). Horizontal bars indicate mean. (d) Clinical arthritis scores from the left legs of F759 (closed 
circles; n = 8) or C57BL/6 (closed triangles; n = 8) mice that received transfers of 5 × 106 Th17 cells as well as CCL20 injections. Clinical arthritis scores 
from the left legs of F759 (open circles; n = 8) or C57BL/6 mice (open triangles; n = 8) after CCL20 injections without Th17 cell transfers are also shown 
(Th17 vs. saline: **, P < 0.01; ***, P < 0.005 for 4, 6, 8, and 11 d). (e) Cells from the joint tissues of F759 mice that received transfers of 5 × 106 Th17 cells in 
the presence or absence of microbleeding were prepared and CCL20 mRNA expression levels were analyzed (untreated vs. microbleeding: *, P < 0.05).  
(f) Clinical arthritis scores from the left legs of F759 mice after CCL20 injections and intravenous transfer of Th17 cells derived from C57BL/6 mice (closed 
circles; n = 8) or IL-17A/ mice (open circles; n = 7; WT vs. IL-17A/ Th17 cells; *, P < 0.05; ***, P < 0.005 for 4, 9, and 11 d). (g) Clinical arthritis scores 
from the left legs of F759 mice (closed circles; n = 7) or IL-6/ F759 mice (open circles; n = 5) after intravenous transfer of 5 × 106 WT Th17 cells plus 
CCL20 injection (*, P < 0.05; **, P < 0.01 for 3, 6, and 10 d). (h) Clinical arthritis scores from the left legs of F759 mice (closed circles; n = 6) or type I  
collagen-Cre STAT3flox/flox F759 mice (open circles; n = 4) after intravenous transfer of 5 × 106 WT Th17 cells and CCL20 injections (*, P < 0.05; ***, P < 0.005 
for 6, 7, and 10 d). (i) Clinical arthritis scores from F759 mice that received transfers of 5 × 106 Th17 cells in the presence of microbleeding and joint injec-
tions of lentivirus carrying shRNA specific for CCL20 (open squares; n = 6) or STAT3 (open triangles; n = 5), or a nontarget sequence (open circles; n = 4; 
nontarget sequence vs. CCL20 specific: ***, P < 0.005 for 11, 12, 13, and 14 d; nontarget sequence vs. STAT3 specific: **, P < 0.01; ***, P < 0.005 for 9, 11, 
12, 13, and 14 d). Mean scores ± SEM were determined as described in Materials and methods. P-values were calculated using Student’s t tests. These 
experiments were performed at least twice independently. Representative data are shown.JEM VOL. 208, January 17, 2011 
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induced arthritis in F759 mice (Fig. 5 f), confirming that   
the accumulation of Th17 cells in the joint is sufficient for   
arthritis development and that antigen recognition is not   
required. Finally, we showed that direct injection of IL-17A 
into  one  joint  induces  arthritis  in  F759,  but  not  control 
C57BL/6, mice (Fig. 6, a and b; and Fig. S1 f). Additionally, 
arthritis did not develop in the leg joints of F759 mice that 
did not receive injections of Th17 cells or IL-17A (Fig. S6, a–e). 
All these data are consistent with the idea that local accumu-
lation of Th17 cells contributes to the development of arthri-
tis in F759 mice by serving as a synovial source of cytokines 
(e.g., IL-17A) and by enhancing IL-6 signaling independent 
of antigen recognition.
DISCUSSION
It is clear that the recognition of specific antigens by auto-
reactive T cells contributes to the tissue specificity of several 
autoimmune diseases (Marrack et al., 2001; Mathis and Benoist, 
2004). In many cases, however, causative tissue-specific anti-
gens recognized by memory/activated CD4+ T cells have not 
been established, even for diseases associated with class II 
MHC alleles (Mocci et al., 2000; Skapenko et al., 2005).   
T cell–dependent tissue-specific diseases in hosts having a 
sufficient number of effector CD4+ T cells and tissues with 
enhanced sensitivity to T cell–derived cytokines.
Local accumulation of Th17 cells contributes  
to the development of arthritis in F759 mice by acting  
as a source of IL-17A
Lastly, we examined whether direct injection of Th17 cells or 
IL-17A into the joint bypasses local events to directly induce 
arthritis in F759 mice. Indeed, injections of Th17 cells but   
not nonpolarized CD4+ T cells or Th1 cells induced arthritis   
(Fig. 5 a). However, none of these treatments elicited arthritis 
in WT mice (Fig. 5 b). Joint injections of Th17 cells derived 
from IL-17A–deficient mice into F759 mice resulted in lower 
clinical scores than injection of Th17 cells from control 
C57BL/6 mice (Fig. 5 c). Injections of Th17 cells from con-
trol mice into IL-6–deficient F759 (Fig. 5 d) or F759 mice in 
which STAT3 was deleted from type I collagen+ cells also   
resulted in lower clinical scores (Fig. 5 e). These results 
strongly suggest that Th17-mediated IL-6 expression in type I   
collagen+ cells plays a role in arthritis development in F759 
mice. Injections of Th17 cells from OT2-RAG/ mice also   
Figure 5.  Th17 cell–mediated induction of the IL-6 amplification loop in joints is critical for arthritis development in F759 mice. (a) Clinical 
arthritis scores from the left legs of F759 mice after left leg joint injections of 5 × 106 Th17 cells (circles; n = 9; *, P < 0.05; ***, P < 0.005 for 3, 4, 5, 6, 7, 8, 
9, 10, 11, 12, 13, and 14 d), 5 × 106 Th1 cells (triangles; n = 4; *, P < 0.05 for 7, 8, 9, 10, 11, 12, 13, and 14 d), and 5 × 106 activated nonpolarized CD4+  
T cells (diamonds; n = 6) compared with those from the left legs of F759 mice after left leg joint injections of saline (squares, n = 9). (b) Clinical arthritis 
scores from the left legs of C57BL/6 mice after left leg joint injections of 5 × 106 Th17 cells (circles; n = 7), 5 × 106 Th1 cells (triangles; n = 4), 5 × 106 
activated nonpolarized CD4+ T cells (diamonds; n = 4), or saline (squares; n = 7). (c) Clinical arthritis scores from the left legs of F759 mice after left leg 
joint injections of Th17 cells derived from C57BL/6 mice (circles; n = 8), IL-17A–deficient mice (triangles; n = 3), or saline (squares; n = 5; WT vs. IL-17A–
deficient Th17 cells: *, P < 0.05; **, P < 0.01 for 4, 6, 7, 8, 9, 10, 11, 12, 13, and 14 d). (d) Clinical arthritis scores from the left legs of F759 mice (circles;  
n = 9) or IL-6–deficient F759 mice (triangles; n = 5) after left leg joint injections of 5 × 106 Th17 cells (*, P < 0.05; **, P < 0.01; ***, P < 0.005 for 4, 6, 7, 8, 
9, 10, 11, 12, 13, and 14 d). (e) Clinical arthritis scores from the left legs of F759 mice (circles; n = 8) or type I collagen-Cre STAT3flox/flox F759 mice (tri-
angles; n = 3) after left leg joint injections of 5 × 106 Th17 cells (*, P < 0.05; **, P < 0.01; ***, P < 0.005 for 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 d). (f) Clinical 
arthritis scores from the left legs of F759 mice after left leg joint injections of Th17 cells derived from C57BL/6 mice (closed circles; n = 4), OT2 RAG2/ 
mice (diamonds; n = 3), or saline (open circles; n = 7; OT2 RAG2/–derived Th17 cells vs. saline: *, P < 0.05; **, P < 0.01; ***, P < 0.005 for 2, 3, 4, 7, 8, 9, 
10, 11, 12, and 14 d). Mean scores ± SEM were determined as described in Materials and methods. P-values were calculated using Student’s t tests. These 
experiments were performed at least twice independently. Representative data are shown.110 Ag-independent induction of MHC2 autoimmunity | Murakami et al.
degree of contribution of each to pathogenesis varies with 
the disease.
The  number  of  cytokine-secreting  effector/memory 
CD4+ T cells increases with age, as the result of an accumula-
tion of pathogen-specific memory T cells and homeostatic 
proliferation  of  CD4+ T  cells. The  resulting  memory/ 
activated CD4+ T cells are increasingly localized in parenchy-
mal organs like the alimentary tract rather than lymphoid   
organs. Therefore, even at steady state, memory/activated 
CD4+ T cells may sometimes migrate and/or stay in tissues at 
risk for autoimmune diseases. Consistent with this, these dis-
eases are more prevalent in older patients who have a large 
population of memory/activated CD4+  T cells, some of which 
secrete cytokines because of homeostatic proliferation and/or 
chronic inflammations (Hasler and Zouali, 2005; Larbi et al., 
2008). Therefore, the first and second steps in the four-step 
model will occur to some degree even in healthy people, par-
ticularly in elderly individuals who have a larger population 
of memory/activated T cells. Autoimmune diseases, including 
RA, however, do not develop in all individuals. The relatively 
low rates of these disorders may reflect the fact that the factors 
that increase the risk of enhancement of local IL-6 signaling 
in affected tissues (the third step) are rare. These factors may 
include products made by viruses or bacteria (Münz et al., 
2009). For instance, HTLV1 infection is a significant risk fac-
tor for arthritis (Uchiyama, 1997), whereas the transgenic ex-
pression of p40 Tax, a product of HTLV1 which activates 
NF-B, causes an RA-like disease in mice (Iwakura et al., 
1991). Indeed, forced expression of p40 Tax in F759 mice has 
been seen to enhance disease development (Ishihara et al., 
2004). Moreover, many viral proteins, including hepatitis C 
virus Core protein and EBNA2 from Epstein-Barr virus, are 
strong STAT3 activators (Yoshida et al., 2002; Muromoto   
et al., 2009). Products from pathogens are also known to stim-
ulate Toll-like receptors, which leads to NF-B activation.   
Because viruses and bacteria also have their own preferential 
target cells and/or tissues, their infections could determine 
the tissue specificity of the disease by enhancing cytokine 
sensitivity in the given tissue. Consistent with this idea, auto-
immune diseases are sometimes induced after infections that also 
increase the number of activated pathogen-specific cytokine- 
secreting CD4+ T cells (Kivity et al., 2009). Tissue sensitivity to 
mechanical stress induced by deterioration through age provides 
another potential trigger or enhancer for autoimmune diseases. 
RA and arthritis in F759 mice are such examples (Falgarone 
et al., 2009; this paper). Interestingly, several lines of evidence 
support a pathogenic role for CD4+ T cells in both diseases. 
These include associations with class II MHC and CD4 mole-
cules, increased numbers of memory/activated CD4+ T cells 
as the disease progresses, and improved outcomes in response 
to suppressions and/or deficiencies in class II MHC molecules, 
CD4+ T cells, and the T cell survival cytokine IL-7. IL-7 fur-
ther increases the homeostatic proliferation of CD4+ T cells 
followed by the development of arthritis in F759 mice (Sawa 
et al., 2006; Ogura et al., 2008). These observations led us to 
ask how arthritis is triggered in the joints of F759 mice, and 
tissue-specific CD4+ recognition of tissue antigen is a likely 
explanation. However, our results do not support this model. 
Rather, we found that an accumulation of activated CD4+  
T cells in the joint is critical for arthritis development in F759 
mice. In fact, local microbleeding-mediated CCL20 expres-
sion induced such an accumulation, resulting in the develop-
ment of arthritis. This, then, may argue for the existence of 
RA subgroups, which would include RA, that are mainly de-
pendent on either autoantibodies (e.g., anti-citrullinated anti-
bodies), tissue-specific antigen-mediated immune responses, 
or inflammatory cytokines like IL-6 and TNF. Consistent 
with this notion, therapies against certain molecules like IL-6 
receptor or TNF do not cure all cases of RA. Thus, certain 
class II MHC–associated tissue-specific autoimmune diseases, 
including some RA subtypes, may be at least partly induced 
by local events that cause an antigen-independent accumula-
tion of effector CD4+ T cells followed by the induction of 
enhanced IL-6 signaling via activation of the IL-6 amplifica-
tion loop in the affected tissue. This is triggered by CD4+  
T cell–derived cytokines.
To explain the development of tissue-specific MHC class II-
mediated autoimmune diseases, including RA, we propose   
a four-step model. This model describes the development of 
certain MHC II–mediated autoimmune diseases that are in-
dependent of tissue-specific antigens. The steps include: (1) 
T  cell  activation  regardless  of  antigen  specificity,  (2)  local 
events inducing tissue-specific accumulation of activated   
T cells, (3) enhanced sensitivity to T cell–derived cytokines in 
a population of cells in the affected tissue, and (4) activation 
of an cytokine-dependent IL-6 amplification loop, which is 
triggered by CD4+ T cell-derived cytokines such as IL-17A. 
It is likely that each step interacts with the others, and the   
Figure 6.  IL-17A in the joints induced the development 
of arthritis in F759 mice. (a) Clinical arthritis scores from the 
left legs of F759 mice after left leg joint injections of 0.1 µg  
IL-17A on days 0, 1, and 2 (circles; n = 5; *, P < 0.05 for 4, 7, 
and 10 d) or F759 mice after left leg joint injections of saline 
(triangles, n = 3). (b) Clinical arthritis scores from the left legs  
of C57BL/6 mice after left leg joint injections of 0.1 µg IL-17A 
(circles; n = 4) or saline (triangles, n = 4) on days 0, 1, and 2. 
These experiments were performed at least three times indepen-
dently. Representative data are shown.JEM VOL. 208, January 17, 2011 
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may contribute to the localized class II MHC–associated auto-
immune diseases via NF-B activation followed by an enhance-
ment of IL-6 signaling in the affected tissues. In support of this 
idea, numerous studies have demonstrated the efficacy of tar-
geting TNF for treating RA and other chronic autoimmune 
diseases, the majority of which involve class II MHC molecules 
(Feldmann  and  Maini,  2001).  Furthermore,  activated  CD4+  
T cells are known to express TNF (Cherwinski et al., 1987; 
Constant and Bottomly, 1997; Williams et al., 2008), whereas 
we have found that a lack of TNF attenuates arthritis in F759 
mice (unpublished data). Moreover, it is interesting that LPS 
administration around the joints induces arthritis in mice that 
have an excess number of Th1 cells (Nickdel et al., 2009). This 
may suggest that LPS-mediated IL-6 production around the 
joints induces the local accumulation of Th1 cells followed by 
activation of the IL-6 amplification loop. Consistent with this, 
combined treatment with IL-6 and IFN- synergistically   
induces IL-6 production, at least in vitro (unpublished data).   
We also found that IL-22 enhances IL-6 expression in the pres-
ence of IL-17A in type I collagen+ cells (Fig. S7 a). However, 
joint injections of shRNA specific for the IL-22 receptor hardly 
suppressed arthritis development after joint injection of Th17 
cells in F759 mice (Fig. S7 b). Therefore, it is likely that IL-22 
from Th17 cells plays a minimal role, at least for Th17 cell–
driven arthritis in F759 mice.
To summarize, in this paper we describe how MHC class II–
associated tissue-specific autoimmune arthritis arises in F759 
mice and we propose a four-step model to explain the pro-
cess. This model provides a possible explanation for why 
tissue-specific antigens recognized by activated CD4+ T cells 
have not been identified in many tissue-specific autoimmune 
diseases associated with class II MHC molecules, including 
RA. We expect that our four-step model will provide new 
and important insight into the immunological mechanisms 
driving autoimmune disease development.
MATERIALS AND METHODS
Mouse strains. C57BL/6 mice were purchased from Japan SLC. F759 mice 
were backcrossed with C57BL/6 mice for >10 generations. IL-6–deficient 
mice  (provided  by  M.  Kopf,  Max-Planck-Institute  of  Immunobiology, 
Freiburg, Germany) were backcrossed with C57BL/6 mice for >10 genera-
tions and were then crossed with F759 mice. Type I collagen-Cre mice   
(provided by G. Karsenty, Baylor College of Medicine, Houston, TX) were 
crossed with STAT3flox/flox mice (provided by S. Akira, Osaka University, 
Osaka, Japan; Takeda et al., 1998). IL-17A–deficient mice on a C57BL/6 
background (Iwakura and Ishigame, 2006) were crossed with F759 mice. The 
C57BL/6/P25 TCR-Tg  mouse  line  was  established  in  our  laboratory 
(Tamura et al., 2004). C57BL/6 OT2 TCR-Tg mice were a gift from W.R. 
Heath  (University  of  Melbourne,  Melbourne, Australia).  IL-17A–GFP 
knockin mice were purchased from Biocytogen. C57BL/6 SJL (CD45.1) 
mice were purchased from The Jackson Laboratory. All mice were maintained 
under specific pathogen-free conditions according to the protocols of Osaka 
University Medical School. All animal experiments were performed accord-
ing to the guidelines of the Institutional Animal Care and Use Committees 
of the Graduate School of Frontier Biosciences and Graduate School of 
Medicine, Osaka University. The protocols for animal experiments used here 
were approved by the Institutional Animal Care and Use Committees of the 
Graduate School of Frontier Biosciences and Graduate School of Medicine, 
Osaka University.
Such stress can induce local events such as microbleeding 
and/or IL-6 expression via activation of NF-B. Moreover, 
these diseases might be associated with various genetic ab-
errations, including a somatic mutation in gp130 molecules, 
which induces STAT3 hyperactivation and numerous muta-
tions in NF-B regulators that activate NF-B signaling   
(Lenz et al., 2008; Compagno et al., 2009; Rebouissou et al., 
2009). In addition, de novo mutations in STAT3 have been 
identified  in  patients  with  hyperimmunoglobulin  E  syn-
drome (Minegishi et al., 2007). Thus, activation of STAT3 
and/or NF-B regulators via local pathogen infections, accu-
mulated pathogen products, and/or genetic mutations may 
play a role in enhancing the sensitivity of affected tissues to 
T cell–derived cytokines.
Microbleeding in the joints may result in the accumulation of 
many different cell types, including red blood cells, neutrophils, 
macrophages, and dendritic cells, as well as memory/activated 
CD4+ T cells including Th17 cells. In this paper, we focused on 
IL-17A expression from Th17 cells accumulating in the joints. 
However,  it  is  reasonable  to  argue  that  microbleeding  could   
accelerate the inflammatory reaction by other means. For exam-
ple, the environment of the joint synovium or the presence of 
dead cells may lead to the release of intracellular stimulants such 
as heme and/or danger-associated molecular patterns (DAMPs) 
including mitochondria (Zhang et al., 2010). These stimulants 
secondarily enhance cell death by heme’s toxic effect. They   
might also induce IL-6 and/or CCL20 expression based on the 
fact that DAMPs from dead cells directly and/or indirectly acti-
vate the NF-B pathway (Bianchi, 2007; Sims et al., 2010).
Interestingly, activation of the IL-17–triggered IL-6 amplifi-
cation loop is also involved in the development of EAE (Ogura 
et al., 2008). Because the model for EAE is dependent on a   
tissue-specific MOG-derived peptide, these results suggest that 
antigen specificity by the effector CD4+ T cells and enhanced 
IL-6 signaling in the affected tissue via the IL-6 amplification 
loop do not always function independently of each other in   
tissue-specific autoimmune diseases. If this is the case, cognate 
antigen recognition by the effector CD4+ T cells could occur 
upstream of the enhanced IL-6 signaling in the affected tissue. 
The antigen specificity of the effector CD4+ T cells may func-
tion initially to target these cells around the affected tissues.   
In other words, the antigen specificity might bypass initial local 
events (like microbleeding in F759 mouse) that induce tissue-
specific accumulation of activated T cells, although some local 
events might increase the efficacy of the tissue accumulation. 
The resulting pool of activated CD4+ T cells around the spe-
cific tissues could enhance local IL-6 signaling as a source for 
cytokines via the IL-6 amplification loop. Thus, regardless of the 
stimulus for the local accumulation of effector CD4+ T cells, 
the resulting inflammatory disease is associated with class II 
MHC molecules if cytokines from the activated CD4+ T cells 
are involved in the disease development. Cytokines other than 
IL-17A may also contribute to class II MHC–associated diseases 
to enhance IL-6 signaling in type I collagen+ cells (fourth step), 
as nonpolarized activated CD4+ T cells, Th1, or IL-17A/ 
Th17 cells induced a mild form of arthritis. TNF, for example, 112 Ag-independent induction of MHC2 autoimmunity | Murakami et al.
Microbleeding  induction. Microbleeding was induced in the joints as   
described previously (Hakobyan et al., 2008). In brief, the knee joint   
capsule of each mouse was punctured with a 30-g needle below the patella 
to induce microbleeding.
Real-time PCRs. A GeneAmp 5700 sequence detection system (ABI) and 
SYBER green PCR Master Mix (Sigma-Aldrich) were used to quantify 
the levels of CCL20 mRNA and HPRT mRNA. Total RNA was prepared 
from mouse embryonic fibroblast cells and synovial tissues using a Gen-
Elute Mammalian Total RNA kit (Sigma-Aldrich) and DNase I (Sigma- 
Aldrich). The PCR primer pairs used for real-time PCRs were as follows: 
mouse  HPRT  primers,  5-GATTAGCGATGATGAACCAGGTT-3  and 
5-CCTCCCATCTCCTTCATGACA-3; mouse IL-6 primers, 5-GTGG-
CAGGTAGAGCAGGAAG-3 and 5-CCACCTGAAAGGCACTCTGT-3; 
and CCL20 primers, 5-ACAGTGTGGGAAGCAAGTCC-3 and 5-CCGT-
GAACTCCTTTGACCAT-3. The  conditions  for  real-time  PCR  were   
40 cycles at 94°C for 15 s followed by 40 cycles at 60°C for 60 s. The relative 
mRNA expression levels were normalized to the levels of HPRT mRNA.
Statistical analysis. Student’s t tests (two-tailed) were used for statistical 
analysis of differences between two groups.
Online supplemental material. Fig. S1 shows histology analysis that con-
firmed arthritis development. Fig. S2 shows cytokine expression in activated 
nonpolarized CD4+ T cells, Th1 cells, and Th17 cells induced in vitro. Fig. S3 
shows clinical arthritis scores from the left legs of F759 mice transferred with 
Th1 or with Th17 cells, followed by microbleeding induction or by joint   
injection of CCL20. Fig. S4 shows the number of IL-17A–expressing Th17   
cells presented in the joints of F759 hosts after microbleeding induction.   
Fig. S5 shows clinical arthritis scores from the right legs of F759 mice or 
C57BL/6 mice after intravenous injections of Th17 cells followed by CCL20 
in the left leg joints. Fig. S6 shows clinical arthritis scores from the right legs 
in various mouse strains after injections into left leg joints of activated non-
polarized CD4+ T cells, Th1 cells, or Th17 cells. Fig. S7 shows that IL-6 ex-
pression in type 1 collagen+ cells after stimulations with IL-17 and/or IL-22 
and clinical arthritis scores from the left legs of F759 mice joint injected with 
Th17 cells in the presence of lentivirus carrying shRNA for non targeting 
sequences, STAT3, or IL-22 receptor . Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100900/DC1.
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